Welcome to our dedicated page for Biolife Solutions SEC filings (Ticker: BLFS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The BioLife Solutions, Inc. (NASDAQ: BLFS) SEC filings page on Stock Titan provides access to the company’s official regulatory documents filed with the U.S. Securities and Exchange Commission. These filings offer detailed information on BioLife’s activities as a developer and supplier of cell processing tools and services and bioproduction products and services for the cell and gene therapy (CGT) and broader biopharma markets.
Through periodic reports such as the Form 10-K annual report and Form 10-Q quarterly reports, investors can review disclosures on BioLife’s Cell Processing, Cold Chain, and Thawing product areas, its focus on biopreservation media and related tools, and the financial impact of divestitures and strategic transactions. These filings also describe the company’s use of GAAP and non-GAAP metrics, its presentation of discontinued operations related to divested subsidiaries, and other elements of its financial reporting framework.
Current reports on Form 8-K highlight specific material events, including quarterly earnings announcements, investor presentations, and the sale of its evo cold chain logistics subsidiary. Proxy materials such as the definitive proxy statement (DEF 14A) provide insight into corporate governance, board composition, executive compensation proposals, and matters submitted to stockholder votes at the annual meeting.
On Stock Titan, each new BioLife filing is captured from EDGAR and paired with AI-powered summaries that explain the key points in clear language. Users can quickly scan annual reports (Form 10-K), quarterly reports (Form 10-Q), and current reports (Form 8-K) to understand changes in BioLife’s cell processing business, portfolio evolution, and governance decisions. The filings page also surfaces information relevant to topics such as equity awards and compensation policies discussed in proxy statements, helping investors interpret the regulatory record behind the BLFS stock.
BioLife Solutions Inc. (BLFS) reported an insider stock sale by a board director. Director Amy DuRoss filed a Form 4 disclosing three open-market sales of BLFS common stock on 11/19/2025, 11/20/2025, and 11/21/2025. The reported transactions were sales of 477 shares at $24.50, 4,523 shares at $24.51, and 1,000 shares at $26.00, all coded as dispositions. After these trades, DuRoss beneficially owned 24,687 shares of BioLife Solutions common stock in direct ownership.
BioLife Solutions, Inc.
BioLife Solutions (BLFS) disclosed insider stock sales by its President and CEO, who is also a Director. The filing reports three open‑market sales of Common Stock: 35,417 shares at a weighted average price of $26.15 on 11/11/2025; 33,418 shares at $25.88 on 11/12/2025; and 31,165 shares at $25.33 on 11/13/2025.
Following these transactions, the executive’s directly held shares moved from 454,581 to 421,163 and then to 389,998. Each price is a weighted average, with individual trades executed within disclosed ranges.
BioLife Solutions (BLFS) reported Q3 results with total revenue of $28.1 million, up from $21.4 million a year ago, and net income of $0.6 million ($0.01 per share). Operating loss narrowed to $0.09 million, aided by $0.8 million in other income. For the first nine months, revenue was $77.4 million and net loss was $15.7 million, reflecting a $15.5 million IPR&D expense tied to the PanTHERA acquisition.
Cash, cash equivalents, and available-for-sale securities totaled $98.4 million at September 30, 2025. Year-to-date, operating cash flow was $15.2 million, investing used $72.7 million (including marketable securities purchases and IPR&D), and financing used $8.4 million as the company repaid $7.5 million on term loans. Shareholders’ equity was $353.7 million.
Management continues to focus on higher-margin bioproduction products after divesting several businesses in 2024. The company completed the PanTHERA transaction (accounted for as an asset acquisition) and, subsequent to quarter-end, signed an agreement to sell SAVSU, which remains in continuing operations for this period.
BioLife Solutions (BLFS) filed an 8-K announcing Q3 2025 results. The company reported that it issued a press release with unaudited financial results and operational highlights for the quarter ended September 30, 2025. The press release is furnished as Exhibit 99.1.
The filing classifies the update under Item 2.02 (Results of Operations and Financial Condition). BioLife’s common stock trades on the Nasdaq under the symbol BLFS.
BioLife Solutions (BLFS) reported an insider transaction on Form 4. Director Joydeep Goswami sold 1,666 shares of Common Stock on 10/24/2025 at a price of $28.99 per share, coded as an open-market sale (S). The transaction was executed under a Rule 10b5-1(c) trading plan effective 12/13/2024. Following this sale, Goswami beneficially owns 44,986 shares, held directly.
BioLife Solutions (BLFS) reported an insider transaction by its President & CEO and Director. On October 22, 2025, the reporting person sold 37,795 shares of common stock at $27.3 per share under a Rule 10b5-1(c) trading plan. Following the sale, the reporting person beneficially owns 489,998 shares, held directly.
The filing notes the 10b5-1 plan was effective October 19, 2023 and was adopted to satisfy tax withholding obligations related to the vesting of restricted stock.
BioLife Solutions (BLFS) filed a Form 4 indicating CTO Sean Werner sold 275 shares of common stock at $27.82 on October 20, 2025. The filing states the trade was executed under a Rule 10b5-1(c) plan adopted effective 07-17-2024 to satisfy tax withholding related to restricted stock vesting. Following the transaction, Werner beneficially owned 26,037 shares, held directly.
BioLife Solutions (BLFS) director Joydeep Goswami reported an open-market sale of 1,334 shares of common stock on 10/16/2025. The transaction was executed at a weighted average price with trade prices ranging from $28.99 to $29.00.
Following the sale, the reporting person beneficially owns 46,652 shares directly. The filing states the trades were made under a Rule 10b5-1(c) trading plan adopted effective 12/13/2024.
BioLife Solutions (BLFS): Casdin Partners Master Fund reported an open‑market sale of 750,000 shares of common stock on 10/15/2025 at a weighted average price of $28.5471, executed in multiple trades within the $28.50–$28.8354 range. After the transactions, 5,957,165 shares were beneficially owned indirectly. The shares are held directly by the Master Fund and may be deemed to be indirectly beneficially owned by Casdin Capital, Casdin Partners GP, and Eli Casdin.